Eli Lilly and Company (VIE:LLYC)
Austria · Delayed Price · Currency is EUR | Market Cap | 1.10T +72.5% |
| Revenue (ttm) | 69.73B +49.6% |
| Net Income | 23.38B +93.6% |
| EPS | 26.72 +94.8% |
| Shares Out | n/a |
| PE Ratio | 46.09 |
| Forward PE | 33.75 |
| Dividend | 5.73 (0.47%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 27 |
| Open | 1,174.60 |
| Previous Close | 1,155.40 |
| Day's Range | 1,174.60 - 1,238.80 |
| 52-Week Range | 699.40 - 1,231.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly price target raised to $1,610 from $1,440 at Jefferies
Jefferies raised the firm’s price target on Eli Lilly (LLY) to $1,610 from $1,440 and keeps a Buy rating on the shares. The firm notes the company posted a strong…
Big, fat demand for weight-loss drugs fuels Eli Lilly stock surge — as market cap hits $1.2 trillion
Eli Lilly stock hit a record high Thursday thanks to a stronger-than-expected earnings report fueled by sales of weight loss drugs Monjuaro and Zepbound.
Thursday's First Moves: FTNT Falls After Earnings, CAT Tumbles, LLY Rises
Fortinet (FTNT) shares sunk after earnings as the cybersecurity company's product revenue slowed. Caterpillar (CAT) showed a similar slowing story in its earnings despite posting a beat.
Eli Lilly CEO Dave Ricks on the obesity market: The room for expansion is dramatic
Eli Lilly, Dave Ricks joins 'Squawk on the Street' to discuss the company blowing past estimates, hike in sales outlook, and growing demand for weight-loss medication.
Eli Lilly Stock (LLY) Soars as Financial Results Crush Wall Street Estimates
The pharma giant raised its sales guidance.
Eli Lilly and Company Earnings Call Transcript: Q3 2026
Q3 revenue grew 39% YoY, and FY2026 revenue guidance rose to $91B–$92B on strong incretin demand and broader portfolio growth. Pipeline advances and major manufacturing investments support future expansion, while price pressure and nonrecurring 2026 items shape the 2027 outlook.
Eli Lilly and Company Earnings release: Q3 2026
Eli Lilly and Company released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Eli Lilly and Company Slides: Q3 2026
Eli Lilly and Company has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Eli Lilly and Company Quarterly report: Q3 2026
Eli Lilly and Company has published its Q3 2026 quarterly earnings report on October 29, 2026.
Morning Movers: Caterpillar lower, Eli Lilly higher after earnings
Stock futures are lower as investors digest yesterday’s Federal Reserve hold and contrasting results from Alphabet and Microsoft. The Fed kept its benchmark interest-rate range unchanged at 3.75%-4%, ...
Eli Lilly's blowout quarter has a $5.5 billion twist
Eli Lilly LLY reported better-than-expected earnings for its fiscal Q3 on Thursday, offering fresh evidence that helps justify its trillion-dollar market cap. Sales reached $24.4 billion, while adjust...
Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound
The pharmaceutical company's third-quarter profit came in at $6.45 billion, or $7.22 a share, compared with $5.58 billion, or $6.21 a share, a year earlier.
Eli Lilly Stock Jumps as Monster Earnings Powered by Mounjaro and Zepbound
Eli Lilly posts earnings that handily top estimates, fueled by strong performance in its metabolic portfolio.
Lilly raises outlook for third time this year as Zepbound sales soar.
The drug continues do dominate the market for prescription weight-loss drugs in the U.S.
Eli Lilly cuts FY26 EPS view to $35.00-$36.00 from $35.50-$36.50
Consensus $34.46. Raises FY26 revenue view to $91B-$92B from $85B-$87B, consensus $88.74B. Raises FY26 tax rate view to 19%-20% from 18%-19%. The company said, “In addition to updates to Revenue…
Eli Lilly reports Q3 EPS $7.48, consensus $6.61
Reports Q3 revenue $24.4B, consensus $22.62B. “Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook,” said David A. Ricks, Lilly chair and…
Eli Lilly hikes sales outlook, as CEO says there's room for ‘dramatic' obesity market expansion
Eli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes t...
Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
Eli Lilly raised its full-year revenue forecast and beat third-quarter earnings expectations on Thursday, propelled by surging demand for injectable weight-loss drugs that could allay investor concer...
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milest...
Novo Stock (NVO) Falls After Another Head-to-Head Obesity Trial Loss to Eli Lilly
Shares of Danish pharma giant Novo ($NVO) edged lower to around $38 on Wednesday afternoon. This came after rival drugmaker Eli Lilly ($LLY) announced results of a head-to-head trial in…
Eli Lilly’s (LLY) Head of International Business Retires
The pharma giant reports financial results on Oct. 29.
Ghabour: Fed "Biggest Risk to Bull Market;" Bullish on MSFT, CRWD, LLY
Eddie Ghabour sees the Fed as the biggest risk to the current bull market. He believes the FOMC has tightened enough and believes a likely interest rate raise in December will strangle equity investor...
Strong Results, Guidance Boost Eli Lilly Shares Ahead of Earnings
Shares of Eli Lilly and Company (LLY) rise 19,899% since Big Money bought big in 1990.
Eli Lilly announces topline results from TRANSCEND-T2D-2 trial of retatrutide
Eli Lilly (LLY) announced topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes. At 80 weeks, retatrutide...
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
Eli Lilly is developing a more potent weight-loss drug called retatrutide. In the first head-to-head trial versus Ozempic, retatrutide takers lost roughly twice as much weight.